RAANANA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma (“Trigone”), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment ...

RAANANA, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trigone Pharma Ltd. a leader in the field of urological diseases, today announced the initiation of a Phase 2 study of TRG-100 in patients with ...

"We are delighted to add NDV-01 to our pipeline as we believe it represents an exceptional value-creation opportunity for Relmada and our investors. The drug development expertise of our Team provides ...

Trigone Pharma Ltd. is a privately-held specialty pharmaceutical company focused on the development of a proprietary sustained-release platform designed to enhance the efficacy and safety of ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...